Drug Information

Drug General Information
Drug ID
D0AE9M
Former ID
DNC012016
Drug Name
Butyl-indol-1-yl-pyridin-4-yl-amine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [534087]
Formula
C17H19N3
Canonical SMILES
CCCCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
InChI
1S/C17H19N3/c1-2-3-13-19(16-8-11-18-12-9-16)20-14-10-15-6-4-5-7-17(15)20/h4-12,14H,2-3,13H2,1H3
InChIKey
OSRPQIAWURAKDF-UHFFFAOYSA-N
PubChem Compound ID
10801657
Target and Pathway
Target(s) Alpha-2C adrenergic receptor Target Info Inhibitor [534087]
Alpha-2B adrenergic receptor Target Info Inhibitor [534087]
Alpha-2A adrenergic receptor Target Info Inhibitor [534087]
KEGG Pathway cGMP-PKG signaling pathway
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
PANTHER Pathway Alpha adrenergic receptor signaling pathway
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathway
Reactome Adrenoceptors
Adrenaline signalling through Alpha-2 adrenergic receptor
Adrenaline,noradrenaline inhibits insulin secretion
G alpha (i) signalling events
G alpha (z) signalling events
Surfactant metabolismR-HSA-390696:Adrenoceptors
G alpha (z) signalling eventsR-HSA-390696:Adrenoceptors
Surfactant metabolism
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Platelet Aggregation (Plug Formation)
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signalingWP58:Monoamine GPCRs
GPCR downstream signaling
References
Ref 534087J Med Chem. 1996 Jan 19;39(2):570-81.Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
Ref 534087J Med Chem. 1996 Jan 19;39(2):570-81.Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.